<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627861</url>
  </required_header>
  <id_info>
    <org_study_id>0712009564</org_study_id>
    <nct_id>NCT00627861</nct_id>
  </id_info>
  <brief_title>Combined Renin Inhibition/Beta-blockade</brief_title>
  <official_title>Renin System Responses to Combined Renin Inhibition and Beta Adrenergic Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism
      responsible for treatment failure is a drug related stimulation of the
      renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat
      hypertension by blocking the RAAS system have been developed. However, the kidney responds to
      these drug treatments by producing greater amounts of renin. This high level of renin can
      reduce the effectiveness of some of these medications, ultimately causing the blood pressure
      to rise. This is one reason why blood pressure can be difficult to control in a certain
      percentage of patients.

      The hypothesis to be tested in the proposed study is that beta-adrenergic blockade
      (β-blockade), when superimposed upon aliskiren, a drug that competitively inhibits plasma
      renin activity (PRA) but stimulates the release of renin by the kidneys (plasma renin
      concentration [PRC]), can suppress the reactive increase in PRC that occurs during aliskiren
      monotherapy.

      The primary aim of this study is to measure plasma renin concentration (PRC) and plasma renin
      activity (PRA) levels during renin inhibition with aliskiren and combined renin
      inhibition/β-blocker treatment to determine whether the addition of a β-blocker attenuates
      the rise in plasma renin concentration (PRC). A secondary aim is to determine whether
      combined treatment further suppresses PRA and blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The renin-angiotensin-aldosterone system (RAAS) plays a central role in the maintenance of
      normal blood pressure (BP) homeostasis. Derangements in the regulation of this system,
      predominantly due to the failure to appropriately suppress renin secretion by the kidney,
      contribute to the pathogenesis of hypertension and its cardiovascular, renal and
      cerebrovascular complications.

      Several classes of antihypertensive medications that interrupt the RAAS have been developed.
      These include agents that block angiotensin II (Ang II) binding to the AT1 receptor (Ang II
      receptor blockers [ARB]), inhibit conversion of Ang I to Ang II (angiotensin converting
      enzyme [ACE] inhibitors), and suppress renal secretion of renin (beta-adrenergic receptor
      blocker). These agents effectively lower BP, particularly in the hypertensive patient with an
      unsuppressed plasma renin activity (PRA) level, and significantly improve survival in
      cardiovascular diseases in which PRA levels are often elevated (e.g., heart failure,
      myocardial infarction).

      Renin secretion is regulated, in part, by feedback inhibition due to Ang II binding to the
      juxtaglomerular cell (JG). Interruption of Ang II generation or its receptor binding during
      treatment with an ACE inhibitor or ARB, respectively, stimulates renin secretion because
      feedback inhibition is attenuated and renal perfusion pressure is reduced. The consequent,
      reactive rise in PRA that occurs during treatment with these drugs can limit their
      antihypertensive efficacy because Ang I and subsequently, Ang II levels increase.

      These observations reinforce the theoretical and practical importance of pharmacologic
      suppression of renin secretion to prevent the reactive rise in PRA that occurs during
      treatment with ACE inhibitors and ARBs. β-blockers suppress renin secretion by inhibiting
      β1-adrenergic receptors located on JG cells. PRA and Ang II levels are highly correlated and
      these decrease commensurately during treatment with a β-blocker.

      Aliskiren is an orally active, non-peptide renin inhibitor. Its antihypertensive efficacy is
      due to the competitive antagonism of the renin-mediated conversion of angiotensinogen to Ang
      I. During aliskiren treatment, PRA and Ang II levels decrease significantly. Unlike
      β-blockade, in which the PRA level decreases as a consequence of reduced renal secretion of
      renin, aliskiren treatment decreases PRA in response to the direct, competitive inhibition of
      renin. Although PRA decreases, the aliskiren-mediated decrease in plasma Ang II level
      stimulates renal renin secretion. Therefore, although aliskiren and β-blockers both decrease
      PRA levels, they have divergent effects on the plasma concentration of renin (PRC):
      β-blockers decrease it and aliskiren increases it. The reactive rise in PRC has potential
      implications regarding the antihypertensive efficacy of aliskiren — high PRC levels
      theoretically can overcome the competitive inhibition of renin by aliskiren, thereby
      increasing PRA, Ang II, and BP.

      Aliskiren has been studied as monotherapy and in combination with other antihypertensive
      drugs, including hydrochlorothiazide, valsartan, and amlodipine. It has not been studied in
      the presence of a β-blocker. Proposals for future studies include pursuing whether or not
      there are hypertensives who are resistant to aliskiren, what the mechanism(s) is for the
      resistance and ways to overcome the resistance.

      This is a prospective, open-label study of the effect of the sequential addition of a
      β-blocker (extended release metoprolol) to aliskiren on the levels of plasma renin activity
      and plasma renin concentration in subjects with uncomplicated hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The renin laboratory used in the study is no longer available.
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Renin Concentration</measure>
    <time_frame>5th, 6th, 7th, 9th, 10th, 11th, 12th weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Renin Activity</measure>
    <time_frame>screening, 4th, 6th, 7th, 9th, 10th, 11th, 12th weeks</time_frame>
    <description>The blood test, plasma renin activity or PRA, is being measured during the visits outlined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>all visits (weekly for 12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren and metoprolol succinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.</description>
    <arm_group_label>Aliskiren and metoprolol succinate</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-release metoprolol</intervention_name>
    <description>50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.</description>
    <arm_group_label>Aliskiren and metoprolol succinate</arm_group_label>
    <other_name>Toprol-XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Twenty subjects with a history of hypertension with the following inclusion criteria will
        be enrolled:

          -  Age 18-80 years

          -  Stage 1 (systolic 140-159 mm Hg or diastolic 90-99 mmHg) or Stage 2 (systolic &gt;160 mm
             Hg or diastolic &gt;100 mmHg) or current treatment with antihypertensive medication.

          -  PRA ≥0.65 ng/ml/h. If PRA is below this level during the screening period, due to
             treatment with a beta-blocker or central α2-receptor agonist, the subject may be
             enrolled and the PRA level re-checked after treatment is tapered off.

        Exclusion Criteria:

          -  History of diabetes requiring pharmacologic treatment with an oral or parenteral
             hypoglycemic agent, including insulin

          -  TIA, stroke or myocardial infarction

          -  History of asthma or COPD

          -  Cockcroft Gault estimated GFR &lt;60 ml/min/1.73 m2

          -  Previous adverse events during treatment with a β-blocker or aliskiren

          -  ALT level twice normal

          -  Secondary forms of hypertension (e.g., renovascular, primary aldosteronism)

          -  PRA&lt;0.65 ng/ml/h after discontinuation of antihypertensive medication

          -  Systolic BP&gt;180 mm Hg, diastolic BP&gt;105 mm Hg

          -  Pregnant or breastfeeding, or planning pregnancy during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon D Blumenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006 Oct 21;368(9545):1449-56. Review. Erratum in: Lancet. 2006 Dec 16;368(9553):2124.</citation>
    <PMID>17055947</PMID>
  </reference>
  <results_reference>
    <citation>Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 Jan;39(1):E1-8.</citation>
    <PMID>11799102</PMID>
  </results_reference>
  <results_reference>
    <citation>Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007 May;20(5):587-97.</citation>
    <PMID>17485026</PMID>
  </results_reference>
  <results_reference>
    <citation>Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 Jul 21;370(9583):221-9. Erratum in: Lancet. 2007 Nov 3;370(9598):1542.</citation>
    <PMID>17658393</PMID>
  </results_reference>
  <results_reference>
    <citation>Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999 May;12(5):451-9.</citation>
    <PMID>10342782</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <results_first_submitted>August 19, 2011</results_first_submitted>
  <results_first_submitted_qc>August 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2011</results_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren and Metoprolol</title>
          <description>Aliskiren was administered for 4 weeks and then Metoprol was added for 2 additional weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren and Metoprolol</title>
          <description>Aliskiren was administered for 4 weeks and then Metoprol was added for 2 additional weeks of treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Renin Concentration</title>
        <time_frame>5th, 6th, 7th, 9th, 10th, 11th, 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren and Metoprolol</title>
            <description>Aliskiren was administered for 4 weeks and then Metoprol was added for 2 additional weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Renin Concentration</title>
          <units>pg/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Renin Activity</title>
        <description>The blood test, plasma renin activity or PRA, is being measured during the visits outlined.</description>
        <time_frame>screening, 4th, 6th, 7th, 9th, 10th, 11th, 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren and Metoprolol</title>
            <description>Aliskiren was administered for 4 weeks and then Metoprol was added for an additional 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Renin Activity</title>
          <description>The blood test, plasma renin activity or PRA, is being measured during the visits outlined.</description>
          <units>ng/mL/h</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <time_frame>all visits (weekly for 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren and Metoprolol</title>
            <description>Aliskiren was administered for 4 weeks and then Metoprol was added for an additional 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <units>mm Hg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 -Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12-Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12-Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren and Metoprolol</title>
          <description>Aliskiren was administered for 4 weeks and then Metoprol was added for 2 additional weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Warren Bobb, N.P.</name_or_title>
      <organization>The Rogosin Institute</organization>
      <phone>212-746-9114</phone>
      <email>wab9006@nyp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

